BNC210 coverage on Channel 9, page-17

Some investors loosing their composure before the release of PTSD top line results.
You can see that in the share price action, as people lighten up to reduce risk.
I am expecting Primary end point to be met, but lots of inconclusive results for secondary indications, simply because the study is not powered enough to give statistically significant results on everything being measured. Future studies can be undertaken with enough power to resolve promising avenues. Any success in this will be a major breakthrough in these fields of treatment. You can't expect BNC210 to be great at everything. There will be much analysis when the results are released. Up to the investor to sort the wheat from the chaff.